Acipimox

Title: Acipimox
CAS Registry Number: 51037-30-0
CAS Name: 5-Methylpyrazinecarboxylic acid 4-oxide
Additional Names: 2-carboxy-5-methylpyrazine 4-oxide
Manufacturers' Codes: K-9321
Trademarks: Olbemox (Pharmacia); Olbetam (Pharmacia)
Molecular Formula: C6H6N2O3
Molecular Weight: 154.12
Percent Composition: C 46.76%, H 3.92%, N 18.18%, O 31.14%
Literature References: Prepn: V. Ambrogi et al., DE 2319834; eidem, US 4002750 (1973, 1977 both to Carlo Erba). Prepn and toxicology: eidem, Eur. J. Med. Chem. 15, 157 (1980). Pharmacological profile: P. P. Lovisolo et al., Pharmacol. Res. Commun. 13, 151, 163 (1981). Pharmacokinetics: L. M. Fuccella et al., Clin. Pharmacol. Ther. 28, 790 (1980); L. Musatti et al., J. Int. Med. Res. 9, 381 (1981). Mechanism of action: K. Aktories et al., Arzneim.-Forsch. 33, 1525 (1983).
Properties: Crystals from water, mp 177-180°. LD50 orally in mice: 3500 mg/kg (Ambrogi).
Melting point: mp 177-180°
Toxicity data: LD50 orally in mice: 3500 mg/kg (Ambrogi)
Therap-Cat: Antilipemic.
Keywords: Antilipemic; Nicotinic Acid Derivatives.
Aclacinomycins Aclatonium Napadisilate Aconine Aconite Aconitic Acid

Acipimox
Skeletal formula
Ball-and-stick model
Systematic (IUPAC) name
5-carboxy-2-methyl-1-oxidopyrazin-1-ium
Clinical data
AHFS/Drugs.com International Drug Names
Legal status  ?
Routes Oral
Identifiers
CAS number 51037-30-0 YesY
ATC code C10AD06
PubChem CID 5310993
ChemSpider 4470534 YesY
UNII K9AY9IR2SD YesY
KEGG D07190 YesY
ChEMBL CHEMBL345714 YesY
Chemical data
Formula C6H6N2O3 
Mol. mass 154.124 g/mol
 YesY (what is this?)  (verify)

Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.

Brands available : Acipicap from Zydus Cadila